MHE January 2023

A solid majority of respondents said vertical integration among providers is the consolidation trend that is most likely to accelerate this year.

Most of the respondents believe vaccination and antivirals have turned COVID-19 into manageable disease, but there is concern about long COVID-19.

The survey also showed that many believe value-based care is being gamed and that chances that it will be successful are small.

Thirty-seven percent of the respondents rated themselves as optimistic about the near-term future of U.S. healthcare.

After some go-go years, Bright Health, Oscar and Clover Health are leaving some markets.

Higher costs for employers and consumers, major layoffs, a decline in the quality of care are some consequences seen by respondents to the Managed Healthcare Executive® State of the Industry survey. Investment in technology that will improve efficiency might be a silver lining.

The nine models geared toward acute and specialty care produced better results than the 12 that focused on primary care and population health.

Survey shows some support but also some doubt about how effective the efforts will be. A sizable minority (43%) of respondents indicated that they believe stronger incentives are needed.

In the political and policy arena, respondents see implementation of the Inflation Recovery Act as having a major effect this year.

Most states have contracted with insurers to manage their Medicaid programs. Connecticut uses administrative services only contracts and a variety of means to manage the care.

As many as 10 Humira biosimilars may be on the U.S. market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.

Respondents ranked labor shortages and closing healthcare disparities the highest when asked what about most important issues facing U.S. healthcare in 2023.

Experts say Democrats and Republicans could work together on telehealth, mental health and physician payment issues in 2023.

Dozens of gene mutations associated with amyotrophic lateral sclerosis have been identified. Drug developers have homed in on a trio of genes.

Preventive care, health insurance literacy and a digital health shakeout are in the crystal ball.